Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Ischemic Stroke in Children and Young Adults with Sickle Cell Disease (SCD) in the Post-STOP Era
source: American Society of Hematology
year: 2015
authors: Janet L. Kwiatkowski, Julie Kanter, Heather J. Fullerton, Jenifer Voeks, Ellen Debenham, David G Brown, Lynette J Brown, Robert J. Adams
summary/abstract:Background: The Stroke Prevention Trial in Sickle Cell Anemia (STOP) and Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) established routine transcranial Doppler ultrasound (TCD) screening with indefinite chronic red cell transfusions (CRCT) for children with abnormal TCD as standard of care. To identify children at high-risk of stroke, annual TCD screening is recommended from ages 2 to 16 years, with more frequent monitoring if the result is not normal. A reduction in stroke incidence in children with SCD has been reported in several clinical series and analyses utilizing large hospital databases when comparing rates before and after the publication of the STOP study in 1998. We sought to determine the rate of first ischemic stroke in a multicenter cohort of children who had previously participated in the STOP and/or STOP 2 trials and to determine whether these strokes were screening or treatment failures.
Subjects and Methods: Between 1995 and 2005, STOP and STOP 2 (STOP/2) were conducted at 26 sites in the US and Canada. These studies included 3,835 children, ages 2 to 16 y with SCD type SS or S-beta-0-thalassemia. Participation in STOP/2 ranged from a single screening TCD to randomization. STOP 2 also had an observational arm for children on CRCT for abnormal TCD whose TCD had not reverted to normal. The Post-STOP study was designed to follow-up the outcomes of children who participated in one or both trials. 19 of the 26 original study sites participated in Post-STOP, contributing a total of 3,539 (92%) of the STOP/2 subjects. After exit from STOP/2, these children received TCD screening and treatment according to local practices. Data abstractors visited each clinical site and obtained retrospective data from STOP/2 study exit to 2012-2014 (depending on site) including follow-up TCD and brain imaging results, clinical information, and laboratory results. Two vascular neurologists, blinded to STOP/2 status and prior TCD and neuroimaging results, reviewed source records to confirm all ischemic strokes, defined as a symptomatic cerebral infarction; discordant opinions were resolved through discussion. For the first Post-STOP ischemic stroke, prior TCD result and treatment history subsequently were analyzed.
organization: Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Medical University of South Carolina; University of California San Francisco, San Francisco; Medical University of South Carolina, Charlestonread more
+myBinderRelated Content
-
Mortality trends and causes of death in persons with sickle cell disease in the United States, 1979-2014Sickle cell disease (SCD)-related mortal...
-
Treatments for priapism in boys and men with sickle cell diseaseBACKGROUND: Sickle cell disease compris...
-
Differences in Brain Oxygen Supply May Explain Silent Strokes in SCD PatientsBrain oxygen supply is different in diff...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
Sickle cell gene linked to elevated risk of developing kidney failureNew research indicates that being born w...
-
A Man With Sickle Cell Disease and HeadacheApproximately 17% of patients with sickl...
-
The Indiana Hemophilia & Thrombosis CenterThe Indiana Hemophilia & Thrombosis ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.